Technology

TMTRx’s approach allows development of intranasal (IN) and intramuscular (IM) treatments 

Fentanyl and fentanyl analogues (FFAs), like all opioids, cause respiratory depression and also a phenomenon called wooden chest syndrome (WCS).

Based on a novel animal model developed by Dr. Torralva, TMTRx has demonstrated a unique mechanism that results in vocal cord closure (VCC) as a result of FFA overdose. 

Based on the unique mechanism of action that FFAs have and subsequent VCC, TMTRx is testing three classes of drugs, individually and in combination with naloxone, to determine their ability to reverse FFA overdose. All three classes have numerous generic drugs that are available for assessment of their ability to reverse FFA overdose. Based on extensive literature survey, TMT has identified several candidates. The combination formulations will be tested in the animal model specifically created to assess respiratory depression, chest wall rigidity, and vocal cord closure.

Patent Portfolio

Compositions for opiate and opioid prevention and reversal, and methods of their use. U.S. Provisional Patent Application No. 2021030812, filed August 8, 2019.

Compositions for opiate and opioid prevention and reversal, and methods of their use. U.S. Provisional Patent Application No. 62/828,914, filed April 3, 2019.

Compositions for opiate and opioid prevention and reversal, and methods of their use. U.S. Provisional Patent Application No. 62/716,291, filed August 8, 2018.

Compositions for opiate and opioid prevention and reversal, and methods of their use. International Patent Application No. PCT/US2019/45786, filed August 8, 2019.

Prophylaxis and reversal of stimulant and opioid/opiate overdose and/or toxic exposure. U.S. Provisional Patent Application No. 62/938,466, filed November 21, 2019. 

Prophylaxis and reversal of stimulant and opioid/opiate overdose and/or toxic exposure. International Patent Application No. PCT/US2020/WO/2021/102328, filed November 27, 2020. 

Methods for opiate and opioid overdose prevention and reversal. U.S. Provisional Patent Application No. 62/982,623, filed February 27, 2020.

Methods for opiate and opioid overdose prevention and reversal. International Patent Application No. PCT/US2020/WO/2021/174116, filed February 26, 2021.